China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
China Resources Pharmaceutical Group Ltd. has successfully completed the acquisition of a 28% interest in Tasly Pharmaceuticals, making Tasly a non-wholly-owned subsidiary. This strategic acquisition is expected to enhance the company’s market position and expand its operational capabilities in the pharmaceutical industry.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on medical and pharmaceutical products. It is involved in the production, distribution, and retail of pharmaceutical products, with a market focus on expanding its influence in the healthcare sector.
YTD Price Performance: -6.62%
Average Trading Volume: 2,135
Technical Sentiment Signal: Strong Sell
Current Market Cap: €4.1B
See more data about 3320 stock on TipRanks’ Stock Analysis page.